Similar articles

• [Therapy of hyperlipoproteinemia in the elderly].

  Parhofer KG, Göke B. Parhofer KG, et al. Internist (Berl). 2003 Aug;44(8):968-76. doi: 10.1007/s00108-003-0942-4. Internist (Berl). 2003. PMID: 14671811 Review. German.
• [Lipid therapy. Prevention of arteriosclerotic cardiovascular diseases].

  Windler E. Windler E. Internist (Berl). 2001 Jan;42(1):92-110. doi: 10.1007/s001080050728. Internist (Berl). 2001. PMID: 11271625 Review. German. No abstract available.
• Matters of controversy regarding lipid therapy for Japanese patients with coronary artery disease.

  Komiyama M, Wada H, Hasegawa K. Komiyama M, et al. Intern Med. 2014;53(8):817-8. doi: 10.2169/internalmedicine.53.2020. Epub 2014 Apr 15. Intern Med. 2014. PMID: 24739600 No abstract available.
• [Current approaches to the diagnosis and correction of atherogenic dyslipoproteinemia].

  Oganov RG, Perova NV. Oganov RG, et al. Kardiologiia. 1989 Oct;29(10):15-22. Kardiologiia. 1989. PMID: 2615152 Russian. No abstract available.
• [Variability of the hypolipidemic action of simvastatin and fluvastatin in patients with primary hyperlipoproteinemia].

  Tvorogova MG, Susekov AV, Semenova OA, Kukharchuk VV, Titov VN. Tvorogova MG, et al. Ter Arkh. 1998;70(12):8-13. Ter Arkh. 1998. PMID: 10067240 Russian.